Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life

Table 3 Summary of efficacy outcomes in the subgroup of patients with comorbidities at week 16 (N = 57)

Outcome	Baseline	Week 16	P-value*
Perennial allergic rhinitis n = 31
RCSS score
Median ± IQR	24.0 ± 13.0	16.0 ± 7.5	< 0.001
RQLQ score
Median ± IQR	3.8 ± 1.1	2.0 ± 1.4	< 0.001
Bronchial asthma n = 46
FEV1 (L) before bronchodilation-liters
Median ± IQR	2.7 ± 0.8	2.8 ± 0.9	< 0.001
Missing, n (%)	2 (4.3)	2 (4.3)	< 0.001
FEV1% of predicted
Median ± IQR	90.5 ± 15.3	96.5 ± 11.5	< 0.001
Missing, n (%)	2 (4.3)	2 (4.3)	< 0.001
ACT score
Median ± IQR	18.0 ± 6.8	24.0 ± 5.0	< 0.001
AQLQ (S) score
Median ± IQR	4.3 ± 2.8	6.0 ± 1.3	< 0.001
Atopic dermatitis n = 10
EASI score
Median ± IQR	34.2 ± 20.0	4.3 ± 1.4	< 0.01
Peak score on NRS for pruritus
Median ± IQR	8.5 ± 1.0	3.0 ± 1.0	< 0.01
Peak score on NRS for sleep
Median ± IQR	8.0 ± 0.8	1.5 ± 2.5	< 0.01
DLQI score
Median ± IQR	24.0 ± 12.5	4.0 ± 1.8	< 0.01
Chronic spontaneous urticaria n = 3
UAS7 score
Median ± IQR	12.0 ± 4.0	0 ± 5.0	> 0.05

ACT, Asthma Control Test; AD, Atopic Dermatitis; AQLQ (S), Asthma Quality of Life Questionnaire (standardized version); DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; FEV1, Forced Expiratory Volume in 1 s; IQR, Interquartile Range; NRS, Numerical Rating Scale; RCSS, Rhinitis Control Scoring System; RQLQ, Rhinitis Quality of Life Questionnaire; UAS7, Urticaria Activity Score;
^*Compared using the Wilcoxon test for paired data. The threshold for statistical significance was set at P < 0.01

ISSN: 1476-7961